DS 1501

Drug Profile

DS 1501

Alternative Names: Anti-siglec-15-antibody-Daiichi-Sankyo; DS1501

Latest Information Update: 11 Feb 2015

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antibodies; Osteoporosis therapies
  • Mechanism of Action Immunomodulators; Siglec-15 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Osteoporosis

Most Recent Events

  • 31 Jan 2015 Phase-I clinical trials in Osteoporosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top